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Summary 
Although diverse signaling events are initiated by stimulation of multichain immune recognition 
receptors on lymphocytes,  it remains unclear as to which specific signal transduction pathways 
are functionally linked to granule exocytosis and cellular cytotoxicity. In the case of natural killer 
(NK) cells, it has been presumed that the rapid activation  of protein kinase C (PKC) enables 
them to mediate antibody-dependent cellular cytotoxicity (ADCC) and "natural" cytotoxicity 
toward tumor cells. However, using cloned human NK cells, we determined here that Fc receptor 
stimulation triggers granule release and ADCC through a PKC-independent pathway. Specifically, 
pretreatment of NK cells with the selective PKC inhibitor, GF109203X (using concentrations 
that fully blocked phorbol myristate acetate/ionomycin-induced  secretion) had no effect on FcR- 
initiated granule release or ADCC.  In contrast,  FcK ligation led to  the rapid  activation  of 
phosphatidylinositol 3-kinase (PI 3-kinase), and inhibition of this enzyme with the selective  inhibitor, 
wortmannin, blocked FcR-induced granule release and ADCC. Additional experiments showed 
that, whereas FcR-initiated killing was wortmannin sensitive and GF109203X insensitive, natural 
cytotoxic activity toward the tumor cell line K562 was wortmannin insensitive and GF109203X 
sensitive. Taken together, these results suggest that: (a) PI 3-kinase activation induced by FcR 
ligation is functionally coupled to granule exocytosis and ADCC; and (b) the signaling pathways 
involved in ADCC vs natural cytotoxieity are distinct. 
critical event in the development of cell-mediated cyto- 
toxicity is the receptor-stimulated  release of granule- 
derived proteins (1). Before cytotoxic lymphocyte activation, 
preformed granules containing an array of cytotoxic and pro- 
teolytic molecules  reside  beneath  the  cell  surface. Upon 
receptor recognition of susceptible targets, intracellular signals 
direct the transport of the granules toward the effector cell- 
target cell interface where they fuse with the plasma mem- 
brane and release their mediators. Previous work has focused 
on the role of phospholipase  C  (PLC)l-derived signals in 
regulating NK cell and CTL secretory responses (for reviews, 
see references 2-5). 
Specifically, protein tyrosine kinase (PTK)-dependent ac- 
tivation of PLC is initiated after  stimulation of NK cells 
through their FcR (6-9) or of T lymphocytes through their 
1 Abbreviations used in  this paper: ADCC,  antibody-dependent  cellular 
cytotoxicity;  PI 3-kinase, phosphatidylinositol  3-kinase; PIP, phospha- 
tidylinositol-4-phosphate;  PKC, protein kinase C; PI.C, phospholipase C; 
and FFK, protein  tyrosine kinase. 
TCR complex (10-14). The subsequent  PLC-catalyzed hy- 
drolysis of phosphoinositides  generates sn-l,2-diacylglycerol 
and inositol-l,4,5-trisphosphate,  which in turn mediate the 
activation of PKC and the mobilization of intracellular cal- 
cium, respectively. Because PKC-activating phorbol esters, 
acting in conjunction with calcium ionophores,  can induce 
granule release from NK cells and CTL (15-17), it has been 
presumed that secretion initiated by cross-linking of multichain 
immune recognition receptors on these cell types is mediated 
via PKC-dependent pathways. Furthermore, it has been pre- 
sumed that the proximal signals controlling FcR- or TCR- 
initiated secretion would be similar to those inducing granule 
release after NK cell recognition of susceptible tumor targets. 
Direct evidence for either of these assumptions  is lacking. 
Recently, it has been shown that Fc3~RIII  - or TCR-initiated 
activation of FFK also results in the induction of a phospha- 
tidylinositol  3-kinase  (PI  3-kinase)-dependent  pathway 
(18-20). PI 3-kinase is a heterodimer composed of a catalytic 
p110 subunit and a regulatory p85 subunit (21-26).  Upon 
activation, PI 3-kinase phosphorylates  phosphoinositides  at 
the D-3 position of the inositol ring to generate such prod- 
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3,4-bisphosphate,  and phosphatidylinositol 3,4,5-trisphosphate 
(27). These phosphoinositides are distinct from those used 
in the classical  PLC-dependent signaling pathway, and it is 
therefore presumed that the lipids themselves are important 
molecules in signal transduction pathways. Specific attention 
has recently focused on the effects of PI 3-kinase on the sorting 
of vacuoles in yeast (28), phtelet-derived growth factor (PDGF) 
receptor endocytosis (29), histamine release from mast cells 
(30), and cytoskdeton changes in thrombin-stimuhted platehts 
(31).  Taken  together,  these experimental  observations sug- 
gest a potential general role for PI 3-kinase in the regulation 
of vesicular transport. 
To investigate whether PKC- and/or PI 3-kinase-depen- 
dent pathways regulate granule release from cytotoxic lym- 
phocytes, one would like to selectively interrupt each pathway 
and determine the  subsequent effects on receptor-initiated 
secretion. With the recent identification  of the bisindolylmald- 
mide GF109203X (32) and the microbial metabolite wort- 
mannin  (30)  as  sdective PKC  and  PI 3-kinase inhibitors, 
respectively, this experimental strategy is now possible. Using 
cloned human NK cells, we report here that FeyRIII-initiated 
granule release and antibody-dependent cdlular cytotoxicity 
(ADCC) are, in fact, reguhted by PKC-independent pathways. 
Rather, the profound inhibition of these functions by wort- 
mannin suggests that FcR-initiated activation of PI 3-kinase 
modulates granule release  from these cells.  In contrast,  the 
inability of wortmannin to inhibit direct antitumor NK cell- 
mediated  cytotoxicity  suggests  that  alternative  signaling 
pathways are used during  this mode of killing. 
Materiah and Methods 
Chemical Reagents and Antibodies.  Ionomycin and GF109203X 
were obtained from Calbiochem-Novabiochem  Corp. (La Jolla, CA). 
Streptolysin-O was purchased from Wellcome Diagnostics (Dart- 
ford, Enghnd). All other chemicals, unless otherwise noted, were 
obtained from Sigma Chemical Co. (St. Louis, MO). The anti- 
Fclk',/III mAb 3G8 (anti-CD16) (33) were purified by affinity chro- 
matography  over protein  A  agarose. F(ab')z fragments  of goat 
anti-mouse IgG were purchased from Organon Teknika (West 
Chester,  PA). The  antiphosphotyrosine  antibody-secreting  hy- 
bridoma, 1G2, was a gift from A. Ik. Frackelton, Jr. (Brown Univer- 
sity, Providence, ILl). 1G2 mAb purification has been previously 
described (34). The rabbit anti-p85 antisera was raised against a 
GST-p85 fusion protein containing p85 amino acid residues 158-724. 
Cell Lines.  K562 (human erythroleukemia cell line) and P815 
(murine mastocytoma call line) were obtained from American Type 
Culture  Collection  (Rockville,  MD).  The  anti-CD16  3G8  hy- 
bridoma was generously provided by D. M. Segal (National Cancer 
Institute/National  Institutes of Health, Bethesda, MD). These cell 
lines were maintained in RPMI 1640 supplemented with 10% bo- 
vine calf serum. Human PBL were isolated from the defibrinated 
blood of healthy donors by Ficoll-Hypaque density gradient cen- 
trifugation.  Human  CD16 +  NK  cell  lines were  isolated  and 
characterized as previously described (6). 
CelIPermeabilization.  NK cell permeabilization was performed 
as previously described (17). Briefly, NK cells were washed twice 
in Ca  z+ and Mga+-free HBSS and resuspended in permeabilization 
buffer (40 mM Pipes, 1.5 mM EGTA, 5 mM Na2HPO4, 10 mM 
MgC12, 80 mM potassium glutamate,  5 mM NaC1, 0.1 mM di- 
thiothreitol, 0.5 mg/ml BSA, and 3 mM ATP, pH 7.2). The amount 
of CaCI2 required to yield the indicated concentration of free Ca  z  § 
in the permeabilized buffer was calculated with the free calcium 
algorithm.  For each sample (total reaction volume, 250/A), 7.5 
x  10  s NK cells were mixed with the indicated stimuli and strep- 
tolysin O  (0.4 U/ml). The reaction mixtures  were incubated at 
37~  for 30 rain and then centrifuged  at 500 g for 10 min.  200 
/A of the supematant  was collected from each sample for subse- 
quent quantitation  by the secretion assay. 
Secretion Assay.  As previously described (17), a fluorescence  assay 
was used to quantitate exocytotic release of the granule-derived en- 
zyme, hexosaminidase, from NK cells. Briefly, duplicate sample su- 
pematants (50 ~1 each) were diluted 1:2 in 250 mM sucrose, 3 mM 
imidazole, 0.1% ethanol,  pH 7.4, and then incubated for 20 rain 
at 37~  with 100/zl of 0.5 mM 4-methylumbdliferyl-2-acetamide- 
2-deoxy-3-D-glucopyranoside  (Research  Products  International 
Corp., Prospect, IL) in 0.1 M sodium citrate and 0.2% Triton X-100. 
Reactions were terminated by the addition  of 2 ml 50 mM gly- 
cine-5 mM EDTA, pH 10.4. Fluorescence was measured with a 
digital fluorometer (model 450; Sequoia-Turner, Mountain  View, 
CA) at excitation and emission wavelengths of 365 and 450 nm, 
respectively. For each experiment,  total intracellular hexosamini- 
dase content was measured after cell lysis with 1% Triton X-100. 
Percent secretion was calculated as: 100 x  ](stimulated release - 
spontaneous release)/(maximum  release -  spontaneous release)]. 
Spontaneous release for all experiments was <20% of maximum 
release. The range of duplicate samples was <10% of the mean. 
Cytotoxicity Assay.  The SlCr-release assays measuring either di- 
rect NK cell-mediated cytotoxicity or ADCC were performed as 
previously described (6). Spontaneous release was <15% of the max- 
imum release for aU experiments. For results expressed as lyric units, 
1 lytic unit is the number of cells required to give 20% specific 
51Cr release. 
PI 3-Kinase Assay.  NK cell clones were cultured in RPMI 1640 
medium supplemented with 10% bovine calf serum for 16 h before 
analysis. For each sample, 107 cells were treated as noted in figure 
legends, then diluted in ice cold lysis buffer (20 mM Tris, pH 7.4, 
137 mM NaC1, 40 mM ~-glycerophosphate, 1 mM CaCI2, 1 mM 
MgCl2,  10%  glycerol,  1%  Triton  X-100,  1 mM  Na3VO4, 10 
/~g/ml leupeptin,  5 /~g/ml aprotinin,  5 /~g/ml pepstatin  A, and 
I mM PMSF). The cleared lysates were immunoprecipitated  with 
either anti-p85 antibody bound to protein A-Sepharose beads, or 
1G2 antibody covalently bound to Sepharose beads. After 45 min 
at 4~  the immunoprecipitates were washed three times with wash 
buffer (20 mM Tris, pH 7.4, 137 mM NaC1, 40 mM B-glycero- 
phosphate, I mM CaC12, I mM MgCI2, 10% glycerol, 1% Triton 
X-100,  1 mM Ya3VO4, and 200 #M adenosine) and twice with 
10 mM Tris, pH 7.4, 100 mM NaC1, 1 mM Na3VO~, and 200/~M 
adenosine. PI-3 kinase assays  were performed as previously described 
(35). The phosphatidylinositol-4-phosphate (PIP) standard was chro- 
matographed in parallel sample lanes and visualized by staining with 
iodine vapors. Radiolabeled phosphoinositides were detected by au- 
toradiography. In addition, 32p was quantitated after scanning the 
TIs  plates using the Radioanalytic Imaging System (model 4000, 
AMBIS, Inc., San Diego,  CA). 
Results 
PKC-independent  Regulation  of FcR-induced Secretion.  It 
remains unclear which signals  generated after FcR ligation 
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pharmacologic activation of PKC can induce secretion from 
NK cells (16,  17), we first evaluated whether PKC plays a 
similar role after FcR stimulation. We have previously shown 
that stimulation of NK cells with a variety of secretagogues 
induces the coordinate release of hexosaminidase and N-c~- 
benzyloxycarlx~yot-lysine  thiobenzyl ester (BLT)-esterase (17). 
Because the fluorescence assay for hexosaminidase has proven 
to be the more sensitive method for measuring low levels 
of granule exocytosis from human NK cells (17), results from 
the hexosaminidase assays are reported in this study. Cloned 
CD16 +, CD3-  NK cells were first exposed to varying con- 
centrations of the selective PKC inhibitor GF109203X (32), 
and then stimulated with either 3G8 mAb (anti-Fc3'RIII)- 
coated polystyrene beads  or  a  combination  of the PKC- 
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Figure 1.  Selective  inhibition of  FcK-induced  secretion  by wortmannin. 
Cloned CD16 +, CD3- human NK cells (7.5 x  10  s cells/sample)  were 
preincubated  for 15 rain at 370C with the indicated  concentrations  of  either 
GF109203X (top) or wortmannin  (bottom).  (Top)  GF109203X-treated  cells 
were then incubated  for an additional 3 h with either anti-FcyRIII  mAb 
(3GS)-coated,  6-#M-diameter  polystyrene  beads (m) or PMA (1 ng/ml) 
and ionomycin  (1 #M) (.). Hexosaminidase  activity rdeased into the 
supematants was quantitated by measuring the conversion  of 4-methyl- 
umbeiliferyl-2-acetamide-2-deoxy-18-1>-glucopyranosi&  into the fluorescent 
4-methylumbdliferone  product. Without GF109203X pretreatment, the 
NK cells stimulated  with anti-FcyRllI-coated  beads or PMA/ionomycin 
released  6.4 and 20.2% of  their total  intracelhlar  he~osaminidase  content, 
respectively.  (Bottom)  Wortm=nn;,~-treated  cells were stimulated  with ei- 
ther anti-Fc'/RIII mAb (3GS)-coated  beads (.), PMA (2 ng/ml), and 
ionomycin  (1 #M) (O), or PMA (1 ng/ml) and streptolysin-0  (0.4 U/ml) 
(@). For streptolysin O-permeabilized  cells, free  calcium concentration 
was maintained  at 10 #M. Intact cells and streptolysin  O-permeabilized 
cells were  incubated  at 37"C with the agonists for 3 and 1 h, respectively. 
Without wortmannin  pretreatment, the NK cells stimulated  with anti- 
Fc3,RIII-coated  beads, PMA/ionomycin,  or PMA/streptolysin-O  released 
6.4, 11.4, and 38.4% of their total intracelhlar he~osaminidase  content, 
respectively. 
activating phorbol ester, PMA, and the calcium ionophore, 
ionomycin. As shown in the top pand of Fig.  1, pretreat- 
merit of NK cells with concentrations of GF109203X that 
fully inhibited PMA/ionomycin-induced secretion did not 
alter FcK-induced granule release. These results suggest that 
although FKC activation can result in granule exocytosis from 
NK cells, Fcg-stimulated granule release is regulated by PKC- 
independent signaling pathways. 
FoR.dependent Granule Release  fwm NK Cells Is Blocked by 
the PI 3-Kinase Inhibitor, Wortmannin.  The novel finding that 
FcR-induced granule exocytosis is  not regulated by PKC 
prompted us to investigate whether PI 3-kinase, a potential 
modulator of vesicular transport (28-31),  might influence 
secretion from NK cells. Because the p85 regulatory subunit 
ofPI 3-kinase can be tyrosine phosphorylated during cellular 
activation and also has an SH2 domain that binds to tyrosine 
phosphorylated proteins during cellular activation (27, 36-39), 
antiphosphotyrosine immunoprecipitates from FcR-stimuhted 
NK cells were assayed for PI 3-kinase activity. Consistent 
with the recent report by Kanakaraj et al.  (18),  we found 
that Fc'yRIII stimulation of NK cells increased phosphotyro- 
sine-associated  PI 3-kinase activity (Fig.  2). Specifically, PI 
3-kinase activity increased within 2  rain of FcR ligation, 
peaked at 10 rains (sixfold increase), and declined by 30 rain. 
To evaluate the functional consequences of this PI 3-kinase 
activation, we characterized the effects of a recently described 
PI 3-kinase inhibitor, wortmannin (30), in this experimental 
system. Wortmannin, a fungal metabolite, has been shown 
to specifically and irreversibly inhibit PI 3-kinase activity at 
nanomolar concentrations by binding to the p110 catalytic 
subunit of PI 3-kinase (30).  To evaluate its effects on cloned 
human NK cells, lysates from drug-treated cells were immu- 
noprecipitated with anti-p85 antibodies and the immunopre- 
cipitates were assayed for PI 3-kinase catalytic activity (Fig. 
3).  Consistent with concentration-inhibition relationships 
observed'in other cell types (30),  wortmannin inhibited PI 
3-kinase with an ICs0 of "~3 nM. Concentrations of wort- 
mannin that fully inhibited PI 3-kinase activity in these NK 
cells had no effect on conjugate formation with susceptible 
targets (as quantitated by flow cytometry) or on FcR-initiated 
tyrosine kinase activation (as detected by antiphosphotyro- 
sine immunoblotting) (data not shown). In parallel studies, 
pretreatment of NK cells with wortmannin potently inhibited 
FcK-induced secretion in a concentration-dependent manner 
with an ICs0 of •2  nM (Fig.  1, bottom). It is important to 
note that although wortm~nnin blocked FcR-induced granule 
release from NK cells,  PKC-dependent release from either 
intact cells stimulated with PMA/ionomycin or permeabil- 
ized cells stimulated with PMA in buffer containing high 
free Ca  2+ concentration was not inhibited by wortmannin 
(Fig.  1, bottom). These data, together with the differential 
effects of GF109203X on NK cell secretion (Fig. 1, top) suggest 
that  FcR-induced secretion is regulated by a PI 3-kinase- 
dependent, PKC-independent pathway. Conversdy, pharmaco- 
logic activation by phorbol esters induces secretion via a sep- 
arate PKC-dependent, PI 3-kinase-independent pathway. 
FcR-dependent Cell-mediated Cytotoxicity Is Blocked by the 
1429  Bonnema  et al. Figure 2.  FcR stimulation induces activation of PI 3-kinase in NK cells. 
Aliquots (107 cells/sample) of cloned NK cells that had been incubated 
without Ib2 for 16 h were stimulated at 37~  for the time indicated with 
anti-Fc3,RIIl mAb (3138; 10 #g/nil) cross-linked with goat F(ab')z frag- 
ments of  anti-mouse  IgG. Antiphosphotyrosine (IG2 mAb) immunoprecipi- 
tates were assayed for PI 3-kinase activity, using phosphatidylinositol  as 
substrate. Phosphoinositides were separated  by TLC and radiolabded prod- 
ucts were visualized by autoradiograpby. (~p arrow) Position of a PIP stan- 
dard that was chromatographed  in a parallel lane. 
PI 3-kinase Inhibitor, Wortmannin.  Because  FcR-induced gran- 
ule exocytosis is believed to deliver the "lethal hit" during 
ADCC, we performed parallel  analyses  evaluating the potential 
roles of PI 3-kinase and PKC in regulating Fc3/RIII-depen- 
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Figure 4.  Wortmannin  inhibits FcR-dependent NK cell-mediated cy- 
totoxicity. Cloned NK cells were preincubated for 15 min at 370C with 
the indicated concentrations of wortmannin, washed, and then incubated 
for 1 h at 370C with either slCr-labeled 3G8 (anti-Fc3,RIIl) bybridoma 
cells (top) or slCr-labeled P815 cells bound to 3G8 mAb (bottom).  Results 
are expressed as specific stCr release in the insets ([11] no wortmannin, 
[,]  0.03 nM wortmannin, ['k] 0.3 nM wortmannin, [l'q], 3 nM wort- 
mannin, [0] 30 nM wortmarmin, and [O] 300 nM wortmannin) or as 
lytic units per 106 cells, where 1 lytic unit is the number of cells required 
to give 20%  specific stCr release. 
dent, cell-mediated killing. Pretreatment of cloned NK cells 
with wortmannin inhibited killing of both the anti-Fcq,  KIII 
mAb-secreting hybridoma, 3G8 (Fig. 4, top), and the P815 
mastocytoma cell line that is normally rendered sensitive to 
NK cell-mediated cytotoxicity by coating with 3G8 mAb 
("reverse ADCC") (Fig. 4,  bottom). Similar to the ICs0 for 
wortmanrtin's inhibition of FcR-induced granule release, wort- 
mannin inhibited FcR-dependent killing of each target cell 
Figure 3.  Inhibition of PI 3-kinase in wortmannin-treated NK cells. 
Cloned NK cells (107 ceUs/sample) were incubated for 30 min at 370C 
with the indicated  concentrations of  wortmannin~  Anti-p85 immunoprecipi- 
tates from cell lysates were then assayed for PI 3-kinase activity. Rediola- 
baled phosphoinositides were separated by TLC, visualized by autoradiog- 
raphy, and quantitated using an Ambis 4000 Radioanalyfic  Imaging  System. 
Radiohbd in phosphatidylinositol  phosphate products from NK ~  treated 
with 300, 30, 3, 0.3, 0.03, or 0 nM wortmannin  was 39, 190, 535, 1,005, 
1,443, or 1,250 cpm,  respectively. 
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Figure  5.  The PKC inhibitor, GF109203X, fails  to inhibit FcR-depen- 
dent NK cell-mediated cytotoxicity. Cloned NK cells were pretrcated 
for 15 min at 37~  with the indicated concentrations of GFlO9203X 
and the incubated for 1 h at 37~  with either SlCr-hbded 3G8 (anti- 
F~RIII) hybridoma cells (top) or slCr-labded I)815 cells bound to 3(;8 
mAb (bottom). 
type (i.e.,  3G8 hybridomas or 3G8 mAb-coated P815 cells) 
with  ICs0's  of "~3  nM.  Wortmannin  also inhibited  FcR- 
dependent killing mediated by either clonal NK cell lines, 
polyclonal NK cell lines,  or NK cells from PBL (data not 
shown). In repeated experiments,  the percent inhibition by 
wortmannin was consistendy less for freshly isolated NK ceils 
than  for IL-2-dependent  NK cell lines.  In contrast  to the 
ability of the PI 3-kinase inhibitor,  wortmannin,  to reduce 
FcR-dependent  NK cell-mediated  killing,  the PKC inhib- 
itor, GF109203X, did not affect this mode of cellular cyto- 
toxicity,  as  measured  against  either  StCr-labded  3G8  hy- 
bridoma cells (Fig. 5, top) or 3G8 mAb-coated P815 cells (Fig. 
5, bottom). Taken together, these data suggest that FcK stim- 
ulation of NK cell granule release and cell-mediated cytotox- 
icity is selectively blocked by the PI 3-kinase inhibitor, wort- 
mannin. 
Separate Signaling  Pathways Used during Alternative  Modes 
of Ng  Cell-mediated  Cytotoxicity.  NK cells can lyse target 
cells either by FcR-dependent cytotoxidty of IgG-coated target 
ceils (iz, ADCC) or by direct antimmor cell-mediated killing. 
In both cases,  granule release from the NK cells appears to 
be required for effective killing. However, it remains unclear 
whether the proximal signals functionally linked to granule 
release  are the same or distinct.  Having demonstrated that 
FcR-dependent cytotoxicity was blocked by the PI 3-kinase 
inhibitor,  wortmannin,  but  not  by  the  PKC  inhibitor, 
GFlO9203X, we emended our analysis with these pharmaco- 
logic inhibitors to direct NK cell-mediated killing of the pro- 
totypical NK-sensitive tumor target,  K562.  Whereas FcR- 
d~pendent killing of the hybridoma, 3G8, was wortmannin 
sensitive (Fig.  6 A,  top),  and GF109203X resistant  (Fig.  6 
B,  top),  killing  of K562 was wortma_nnln resistant  (Fig.  6 
A, bottom) and GF109203X sensitive (Fig. 6 B, bottom). These 
data suggest that although PI 3-kinase activation appears to 
Figure  6.  FoR-dependent  cytotoxicity  and direct an- 
titumor cytot~icity are reguhted by separate  signaling 
pathways. Cloned NK cells were preincubated for 15 
rain at 37~  with the indicated concentrations of ei- 
ther wortmannin (,4) or GFlO9203X  (B). Drug-treated 
ceUs were then incubated for 1 h with either StCr- 
labeled 3G8 (anti-Fc'yRIII) hybridoma cells (top) or 
slCr-labeled K562 tumor cells (bottom). 
1431  Bonnema  et al. be critical for FcR-induced granule release and ADCC, a sep- 
arate PKC-dependent pathway appears to regulate direct NK 
cell-mediated antitumor killing. 
Discussion 
Cytotoxic lymphocyte  recognition of susceptible target cells 
elicits a diverse array of second messengers and the subse- 
quent development of pleiotropic responses, including effects 
on granule release, cellular cytotoxicity, cytokine gene tran- 
scription, and cell surface receptor expression (2-5, 40, 41). 
The heterogeneity of these biological responses has compli- 
cated attempts to link distinct proximal signaling events with 
specific downstream functional responses. In this study, we 
selectively  inhibited separate signaling pathways generated after 
FcR ligation in NK ceUs and characterized the resulting effect 
on granule release and FcR-dependent cytotoxidty. Our results 
suggest that FcR stimulation of PI 3-kinase in NK cells is 
associated with both granule exocytosis and the generation 
of cellular cytotoxicity. 
Early studies focused on the PTK-catalyzed  activation of 
PLC as a central event during lymphocyte activation (for 
reviews, see references 2-5). With the subsequent demon- 
stration that PKC-activating phorbol esters together with cal- 
cium ionophores could induce granule release from NK and 
T cells (15-17), the consensus view was that FcR- and TCR- 
initiated secretory responses are controlled by PKC-dependent 
pathways. This notion was further bolstered by demonstra- 
tions that PKC could regulate granule exocytosis in other 
secretory cell types (e.g.,  mast calls, chromaffin cells, etc.) 
and could phosphorylate granule-associated proteins (42-45). 
To determine whether FcR- or TCK-initiated granule release 
is, in fact, mediated via a PKC-dependent pathway, one would 
like to assess the effects of selective and potent PKC inhibi- 
tors on this process. However, to date, most of the reported 
PKC inhibitors display poor selectivity both in vitro and in 
vivo. For example, H7 inhibits with similar potency PKC, 
cAMP- and cGMP-dependent protein kinase (ICs0 values of 
3-6/~M) (46). In addition, staurosporine, a potent PKC in- 
hibitor (ICs0 =  10 riM) also effectively inhibits various PTK 
activities (47). In contrast, a recent report (32) characterizes 
the highly selective and potent (ICs0  =  10 riM) effects of 
the bisindolylmaleimide  GF109203X on PKC. Using this in- 
hibitor, we report here that concentrations of GF109203X 
that fully block PMA-ionomydn-induced  secretion from NK 
cells had no effect on FcK-initiated granule release. This re- 
sult suggests that although there is a PKC-dependent pathway 
in NK cells that can modulate granule exocytosis,  Fclk-initiated 
secretion is regulated by a PKC-independent pathway. 
Recent attention has focused on PI 3-kinase as a separate 
second messenger system involved in cellular activation (27). 
This enzyme is activated by a diverse array of receptors with 
intrinsic or associated FFK activities,  including the PDGF, 
epidermal growth factor, CSF-1, insulin, and IL-2 receptors 
(for a review, see reference 27). Most recently, TCR and FcR 
ligation have also been shown to induce PI 3-kinase activa- 
tion (18-20).  Yet, the downstream functional consequences 
of PI 3-kinase activation remain unclear, again due to di~cul- 
ties in sdectively inhibiting this pathway. However, a recent 
report (30) highlights the potent inhibitory activity of the 
fungal metabolite, wortmannin, on PI 3-kinase.  Whereas 
wortmannin was originally characterized  as an inhibitor of 
myosin light chain kinase when used at micromolar concen- 
trations (48), additional studies (30) indicated that at nearly 
100-fold lower concentrations, wortmannin selectively and 
irreversibly inhibits PI 3-kinase. Wortmannin binds to the 
100-kD catalytic subunit of PI 3-kinase resulting in inhibi- 
tion with an ICs0 of 2 nM (30). We report here that wort- 
mannin similarly inhibits PI 3-kinase activity in NK cells with 
an ICs0 of 3 nM and, also inhibits FcK-initiated secretion 
and cellular cytotoxicity with similar potency. These data sug- 
gest that PI 3-kinase activation in NK cells is associated with 
FcK-initiated granule release and ADCC. 
Increasing information implicating potential role for PI 
3-kinase in vesicular transport: (a) VPS34, a homolog of the 
catalytic  subunit of PI 3-kinase,  has been identified in the 
yeast Saccharomyces cerevisiae (28). Yeast strains with VPS34 
deletions or containing VPS34 point mutations exhibit se- 
vere defects in the sorting of vacuolar proteins (b) during 
thrombin-stimulated secretion from platelets,  PI 3-kinase 
associates with the membrane cytoskeleton (31); (c) muta- 
tion of the PI 3-kinase binding site on the PDGF receptor 
alters endocytic trafficking of this receptor after growth factor 
binding (29); (d) pretreatment of the rat basophilic leukemia 
cell line, RBL-2H3, with wortmannin inhibits FceRI-initiated 
histamine release (30). Our results extend these analyses by 
demonstrating that ADCC, which requires the formation of 
a microtubule-organizing center (49) and subsequent granule 
release at the effector-target interface, appears to require PI 
3-kinase  activation. 
P1 3-kinase activity can be altered by multiple factors. PI 
3-kinase associates with receptor proteins and other signaling 
molecules that contain a tyrosine phosphorylated consensus 
sequence, thus allosterically modulating its potential activity 
(36-39,  50-52). Tyrosine and/or serine-threonine phosphory- 
lations may also modulate its enzymatic activity (52-54). In 
addition, recent reports indicate that p85,  the regulatory 
subunit of PI 3-kinase,  associates with the SH3 domain of 
src family PTK (55, 56) and this interaction can increase PI 
3-kinase catalytic activity (57). Because FcR ligation results 
in the rapid activation of p56  ~k (9, 58-60), and FFK activa- 
tion appears to be requisite for granule release and ADCC 
(61, 62), future work will need to focus on the role of p56  ~k 
itself or the proximal substrates of this FFK in coupling FcK 
stimulation to PI 3-kinase  activation. 
Finally, data presented here indicate that signaling events 
regulating granule release after recognition of Ab-coated targets 
(i.e., ADCC) vs susceptible  tumor targets (i.e., direct NK 
cell-mediated cytotoxicity) are distinct. Early studies on NK 
cell activation focused on similarities  in signaling initiated 
during these alternative modes of killing, i.e., early PTK ac- 
tivation, inositol phosphate release, and increase in intracel- 
lular free Ca  2+  (4,  6-9,  61-64).  However, we previously 
reported that pretreatment of NK cells with PKC-activating 
1432  FcR Stimulation  of PI 3-Kinase Is Associated  with Secretion  and Killing phorbol esters had differential regulatory effects on these al- 
ternative forms of NK cell activation  (65).  In this report, 
we extend this analysis by comparatively evaluating the effects 
of wortmannin and GF109203X on secretion and killing in- 
duced by these separate modes of NK cell activation. These 
data  suggest  that  although  FcR-initiated  effects on  these 
processes proceed through PI 3-kinase--dependent pathways, 
direct recognition of susceptible tumor targets initiates granule 
release and killing through PKC-dependent pathways. These 
results point out that: (a) ADCC and direct natural cytotox- 
icity are triggered  by fundamentally  different biochemical 
events; and (b) it may be feasible to differentially modulate 
the effector functions  of NK cells  in patients. 
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